Hodis E, Triglia ET, Kwon JYH, et al. Stepwise-edited, human melanoma models reveal mutations’ effect on tumor and microenvironment. Science. 2022;376(6592):eabi8175. doi:10.1126/science.abi8175.

Peterson RT, Link BA, Dowling JE, Schreiber SL. Small molecule developmental screens reveal the logic and timing of vertebrate development. Proc Natl Acad Sci U S A. 2000;97(24):12965-9. doi:10.1073/pnas.97.24.12965.

Crawford NG, Kelly DE, Hansen MEB, et al. Loci associated with skin pigmentation identified in African populations. Science. 2017;358(6365). doi:10.1126/science.aan8433.

Karlsson EK, Baranowska I, Wade CM, et al. Efficient mapping of mendelian traits in dogs through genome-wide association. Nat Genet. 2007;39(11):1321-8. doi:10.1038/ng.2007.10.

Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell. 2004;6(6):565-76. doi:10.1016/j.ccr.2004.10.014.

Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485(7399):502-6. doi:10.1038/nature11071.

Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251-63. doi:10.1016/j.cell.2012.06.024.

Jalili A, Wagner C, Pashenkov M, et al. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst. 2012;104(21):1673-9. doi:10.1093/jnci/djs373.

Johannessen CM, Johnson LA, Piccioni F, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013;504(7478):138-42. doi:10.1038/nature12688.

Konieczkowski DJ, Johannessen CM, Abudayyeh O, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014;4(7):816-27. doi:10.1158/2159-8290.CD-13-0424.